Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 5/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 5/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593108 | 0.90 | NR1H2 (0.42) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL21593106 | 0.90 | NR1H2 (0.39) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL21593191 | 0.89 | NR1H2 (0.38) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL21593189 | 0.88 | NR1H2 (0.37) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL21593084 | 0.87 | NR1H2 (0.42) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL29836554 | 0.87 | NR1H2 (0.38) | NR1H2BRAF | |
| SCHEMBL21593192 | 0.87 | NR1H2 (0.38) | NR1H2BRAF | |
| SCHEMBL21593118 | 0.86 | NR1H2 (0.36) | NR1H2HTR6ACACB | |
| SCHEMBL21593117 | 0.86 | NR1H2 (0.34) | NR1H2ESR2HTR6ACACB | |
| SCHEMBL23762175 | 0.85 | UCHL1 (0.35) | NR1H2CSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NR1H2 1422/4885RET 2094/4885ESR2 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.